Cowen reaffirmed their buy rating on shares of Incyte (NASDAQ:INCY) in a research note released on Tuesday.

Several other equities analysts have also recently issued reports on INCY. Evercore ISI initiated coverage on shares of Incyte in a research note on Wednesday, August 16th. They set an in-line rating and a $135.00 target price on the stock. BMO Capital Markets restated an outperform rating and set a $172.00 target price on shares of Incyte in a research note on Monday, August 28th. Oppenheimer restated a hold rating and set a $135.00 target price on shares of Incyte in a research note on Thursday, August 31st. J P Morgan Chase & Co restated a buy rating and set a $149.00 target price on shares of Incyte in a research note on Thursday, August 31st. Finally, Raymond James Financial upgraded shares of Incyte from a market perform rating to an outperform rating and set a $159.00 target price on the stock in a research note on Monday, September 11th. One analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Incyte currently has an average rating of Buy and an average target price of $145.65.

Shares of Incyte (INCY) traded up $0.03 during trading on Tuesday, reaching $93.71. 1,430,700 shares of the company were exchanged, compared to its average volume of 1,918,704. Incyte has a 52 week low of $93.49 and a 52 week high of $153.15. The company has a current ratio of 4.82, a quick ratio of 4.81 and a debt-to-equity ratio of 0.01.

Incyte (NASDAQ:INCY) last announced its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.06 by $0.11. The company had revenue of $381.50 million for the quarter, compared to analysts’ expectations of $360.34 million. Incyte had a negative net margin of 10.90% and a negative return on equity of 12.91%. Incyte’s revenue was up 41.6% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.19 EPS. analysts expect that Incyte will post -1.33 earnings per share for the current fiscal year.

In other news, EVP Reid M. Huber sold 696 shares of the company’s stock in a transaction dated Friday, December 1st. The shares were sold at an average price of $98.01, for a total transaction of $68,214.96. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker purchased 100,000 shares of Incyte stock in a transaction dated Friday, September 8th. The shares were acquired at an average cost of $132.00 per share, with a total value of $13,200,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 104,334 shares of company stock valued at $11,992,011 in the last ninety days. Insiders own 17.70% of the company’s stock.

Institutional investors have recently added to or reduced their stakes in the stock. Tower Research Capital LLC TRC increased its holdings in Incyte by 13.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after acquiring an additional 108 shares in the last quarter. Seven Eight Capital LP purchased a new stake in Incyte in the 2nd quarter worth approximately $129,000. IFP Advisors Inc increased its holdings in Incyte by 9.9% in the 2nd quarter. IFP Advisors Inc now owns 1,146 shares of the biopharmaceutical company’s stock worth $144,000 after acquiring an additional 103 shares in the last quarter. Sun Life Financial INC increased its holdings in Incyte by 9,069.2% in the 2nd quarter. Sun Life Financial INC now owns 1,192 shares of the biopharmaceutical company’s stock worth $150,000 after acquiring an additional 1,179 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA increased its holdings in Incyte by 130.4% in the 2nd quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,325 shares of the biopharmaceutical company’s stock worth $177,000 after acquiring an additional 750 shares in the last quarter. 90.86% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and reposted in violation of US and international copyright law. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/06/incytes-incy-buy-rating-reaffirmed-at-cowen.html.

About Incyte

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Analyst Recommendations for Incyte (NASDAQ:INCY)

Receive News & Stock Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related stocks with our FREE daily email newsletter.